The effectiveness opens the door for selling stockholders to immediately resell shares, adding near-term selling pressure. Monitor for any Form 4 filings or prospectus supplements indicating actual sales. The existing going concern and Nasdaq compliance issues compound the bearish outlook.
Price Chart
Executive Summary
GT Biopharma's S-1 registration (File No. 333-299408) became effective on October 20, 2026, covering up to 9,723,057 shares of common stock for resale by selling stockholders. The company will not receive any proceeds, and the offering adds dilution overhang on top of existing going concern and Nasdaq compliance risks.
Key Facts
- S-1 registration effective October 20, 2026 (File No. 333-299408)
- Covers up to 9,723,057 shares for resale by selling stockholders
- Company receives no proceeds from the offering
- Prior S-1 filing noted going concern qualification and Nasdaq non-compliance
- Outstanding warrants for 57.9M shares at $0.62 weighted average exercise price vs. $0.27 stock price create massive dilution overhang
Financial Impact
Up to 9.7M shares of potential dilution; no proceeds to company
Risk Factors
- Immediate selling pressure from stockholder resales
- Dilution overhang from outstanding warrants (57.9M shares)
- Nasdaq delisting risk if $1 bid price not regained
- Going concern qualification indicates financial distress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003305 |
| Document: 9999999995-26-003305-index.html | 9999999995-26-003305 |
| Document: 9999999995-26-003305.txt | 9999999995-26-003305 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | EFFECT | $5.41 | awaiting T+5 | — | $5.07 (+6.28%) |
Oct 13, 2026 13d ago | DEF 14A | $6.21 $5.41 | ▲ +12.88% | ▲ +13.34% | $5.07 (+18.36%) |
Oct 9, 2026 17d ago | S-1 | $6.80 $6.69 | ▲ +1.62% | ▲ +0.12% | $5.07 (+25.44%) |
Sep 25, 2026 4w ago | 8-K | $6.80 $6.16 | ▼ −9.41% | ▼ −10.62% | $5.07 (−25.44%) |
Sep 15, 2026 5w ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $5.07 (+43.67%) |
Sep 3, 2026 7w ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $5.07 (+1908.72%) |
Aug 14, 2026 10w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $5.07 (−1612.84%) |
May 22, 2026 22w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $5.07 (−1052.27%) |
Apr 30, 2026 25w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $5.07 (−1378.13%) |
Apr 7, 2026 28w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $5.07 (+1127.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers